Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$9.89 +5.1%	$27.17	$47.60 ▼ $105.00	$286.66M	0.95	14,153 shs	2.14 million shs
BNTC Benitec Biopharma	$14.61 -2.2%	$14.42	$6.66 ▼ $17.15	$383.51M	0.44	43,016 shs	182,501 shs
CMPS COMPASS Pathways	$4.63 -3.5%	$4.09	$2.49 ▼ $8.54	$433.18M	2.25	929,812 shs	2.10 million shs
JUSHF Jushi	$0.28 -5.4%	$0.33	$0.22 ▼ $0.69	$54.27M	-1.18	54,673 shs	62,764 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	+46.30%	+35.11%	-88.92%	-81.89%
BNTC Benitec Biopharma	0.00%	-11.35%	+10.77%	+1.88%	+112.35%
CMPS COMPASS Pathways	0.00%	+5.47%	+6.19%	+48.87%	-25.80%
JUSHF Jushi	0.00%	+0.36%	-10.97%	-1.43%	-52.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	2.5031 of 5 stars	3.6	2.0	0.0	0.0	2.9	2.5	0.0
CMPS COMPASS Pathways	1.7083 of 5 stars	3.5	3.0	0.0	0.0	0.0	0.8	0.6
JUSHF Jushi	1.0127 of 5 stars	0.0	3.0	0.0	0.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
BNTC Benitec Biopharma	3.22	Buy	$23.83	63.13% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	306.77% Upside
JUSHF Jushi	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest JUSHF, CMPS, AVTE, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
4/10/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$18.00 ➝ $20.00
3/28/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/24/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
BNTC Benitec Biopharma	$80K	4,793.91	N/A	N/A	$4.68 per share	3.12
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
JUSHF Jushi	$257.52M	0.21	N/A	N/A	($0.26) per share	-1.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	N/A
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
JUSHF Jushi	-$48.78M	-$0.24	N/A	N/A	N/A	-18.54%	N/A	-10.71%	8/6/2025 (Estimated)

Latest JUSHF, CMPS, AVTE, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	JUSHF Jushi	-$0.06	-$0.09	-$0.03	-$0.09	$66.23 million	$63.85 million
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A
3/27/2025	Q4 2024	AVTE Aerovate Therapeutics	-$6.65	-$6.65	N/A	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
JUSHF Jushi	N/A	N/A	N/A	N/A	N/A

Latest JUSHF, CMPS, AVTE, and BNTC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
BNTC Benitec Biopharma	0.01	14.80	14.80
CMPS COMPASS Pathways	0.11	10.18	10.18
JUSHF Jushi	N/A	1.13	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
BNTC Benitec Biopharma	52.19%
CMPS COMPASS Pathways	46.19%
JUSHF Jushi	21.68%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
BNTC Benitec Biopharma	1.30%
CMPS COMPASS Pathways	3.93%
JUSHF Jushi	21.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
JUSHF Jushi	1,234	196.63 million	154.04 million	Not Optionable

JUSHF, CMPS, AVTE, and BNTC Headlines

Recent News About These Companies

3 Top Marijuana Stocks If You Plan To Make A Profit In The Cannabis Sector

June 16, 2025 | marijuanastocks.com

Jushi Holdings Inc. Announces Voting Results of Annual Shareholders' Meeting

June 3, 2025 | globenewswire.com

Jushi Holdings Inc. Announces Voting Results of Annual Shareholders’ Meeting

June 3, 2025 | financialpost.com

3 Marijuana Stocks That Make The Cannabis Industry Better

June 2, 2025 | marijuanastocks.com

Jushi Holdings Inc. (OTCMKTS:JUSHF) Sees Large Drop in Short Interest

June 2, 2025 | marketbeat.com

Jushi Holdings Inc. Earnings Call: Mixed Sentiments and Strategic Expansion

May 9, 2025 | tipranks.com

Jushi Holdings Inc. (JUSHF) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Jushi Holdings Inc. (JUSHF) Reports Q1 Loss, Lags Revenue Estimates

May 8, 2025 | zacks.com

Jushi Holdings Reports Q1 2025 Financial Results and Expansion Plans

May 8, 2025 | tipranks.com

Jushi Holdings Inc. Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Jushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | financialpost.com

Jushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | globenewswire.com

Economic impact of U.S. cannabis industry set to double over next six years

April 25, 2025 | msn.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock News

April 23, 2025 | gurufocus.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock News

April 23, 2025 | gurufocus.com

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025

April 23, 2025 | globenewswire.com

Jushi Holdings Expands Ohio Presence with New Mansfield Dispensary

April 18, 2025 | tipranks.com

Jushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Mansfield in Ohio, Expanding Its Statewide Retail Footprint

April 18, 2025 | globenewswire.com

Former COO alleges Jushi fired him for trying to maintain safety measures

April 5, 2025 | greenmarketreport.com

Jushi Holdings announces Ohio retail updates, opening of Beyond Hellow Warren

March 19, 2025 | msn.com

Jushi Holdings Expands Ohio Presence with New Dispensary Opening

March 19, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUSHF, CMPS, AVTE, and BNTC Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$9.89 +0.48 (+5.10%)

As of 06/20/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Benitec Biopharma NASDAQ:BNTC

$14.61 -0.33 (-2.21%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.56 -0.05 (-0.38%)

As of 06/20/2025 04:11 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

COMPASS Pathways NASDAQ:CMPS

$4.63 -0.17 (-3.54%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.59 -0.04 (-0.86%)

As of 06/20/2025 07:47 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Jushi OTCMKTS:JUSHF

$0.28 -0.02 (-5.41%)

As of 06/20/2025 03:58 PM Eastern

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time